OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update

Authors: Spigel, D.R. ¹, Ahn, M.-J. ², Majem, M. ³, Medina Rodríguez, L. ⁴, Lee, K.H. ⁵, Carcereny, E. ⁶, Hernández, A.A. ⁷, Insa, A. ⁸, Cho, E.K. ⁹, Besse, B. ¹⁰, Rha, S.Y. ¹¹, Weiss, J. ¹², D'Arcangelo, M. ¹³, Im, S.-A. ¹⁴, Kim, S.-W. ¹⁵, Carneiro, B.A. ¹⁶, Gadgeel, S.M. ¹⁷, Mitchell, P. ¹⁸, Asare, J.M. ¹⁹, Gainer, S.D. ¹⁹, Achour, I. ¹⁹, Subramaniam, D.S. ¹⁹, Felip, E. ²⁰

Source: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S33-S34

1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

Authors: Voss, M.H., Garmezy, B., Kim, S.H., Maroto Rey, J.P., Mansinho, A.B., Rodriguez-Vida, A., Oliveira, J., van Dongen, M., Rodríguez, L. Medina, Negrier, S., Tran, B., Carneiro, B.A., Alvarez, E. Castanon, Rha, S.Y., Wang, Y., Gainer, S.D., Tang, Z., Achour, I., Asare, J.M., Albiges, L.

Source: In Annals of Oncology October 2023 34 Supplement 2:S1012-S1012